|
The following information was reported to gore through the pivotal study for the gore® ascending stent graft in the treatment of lesions of the ascending aorta (asg device): on (b)(6) 2024, the patient was implanted with gore® tag® thoracic branch endoprosthesis (tbe aortic component and side branch) and a gore® tag® conformable thoracic stent graft with active control system for a thoracic dissection.On (b)(6) 2024, it was reported that images revealed a type iiia endoleak (a/e#3).Reportedly on (b)(6) 2025, a reintervention occurred to treat type iii endoleak, between the tgmr373715/(b)(6) and tac123715c/(b)(6) devices.The physician sealed with ballooning and the type iii endoleak was resolved.The patient tolerated the procedure.No further information is available.
|
|
The gore® tag® conformable thoracic stent graft with active control system instructions for use state that adverse events that may occur and require intervention include endoleak.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may have not been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|